Search results for "From ACP Journal Club"
In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs
A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021
Metformin use was linked to hospitalization for acidosis at 6 y only in patients with eGFR
The results are in accordance with guidelines and regulatory policy recommendations that have extended use of metformin to individuals with mild to moderate kidney impairment, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2018/11/09/6.htm
9 Nov 2018
Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM
A meta-analysis from earlier this year that compared the effects of metabolic surgery and medical treatment found 10 studies to include, only three of them randomized controlled trials.
https://diabetes.acponline.org/archives/2018/08/10/7.htm
10 Aug 2018
Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes
The evidence favors glucagon-like peptide 1 agonists and, particularly, sodium–glucose cotransporter 2 inhibitors for type 2 diabetes, but the benefits in type 1 diabetes remain speculative, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/08/10/8.htm
10 Aug 2018
Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulfonylureas increases hypoglycemia
Adding dipeptidyl peptidase-4 (DPP-4) inhibitors to sulfonylureas was associated with 1 excess case of hypoglycemia for every 17 patients in the first 6 months of treatment, the systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2016/09/16/5.htm
16 Sep 2016
In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM
A industry-funded trial found improved glucose control in men randomized to testosterone injections, but some of its claims were exaggerated, and routine use of testosterone therapy to prevent or reverse type 2 diabetes is not recommended, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/05/14/7.htm
14 May 2021
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function
The results of the CANVAS trial are promising for patients with type 2 diabetes mellitus (T2DM) and early chronic kidney disease, but ongoing research should provide more convincing data, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/03/08/6.htm
8 Mar 2019
In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER
Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/05/11/7.htm
11 May 2018
Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes
An ACP Journal Club commentary recommends advising patients with type 2 diabetes who don't smoke and who take metformin to also consider increasing their soluble fiber intake by more than 10 g/d.
https://diabetes.acponline.org/archives/2019/06/14/6.htm
14 Jun 2019
In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events
The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2018/06/08/7.htm
8 Jun 2018